Cladribine tablets: Completed Phase III enrollment

Merck's Merck Serono S.A. unit completed enrollment of 617 patients at risk of developing MS in the double-blind, placebo-controlled, international Phase III ORACLE MS trial evaluating 2 dose regimen...